- Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease.
- The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects.
- Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials.
- Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three.
- As of Nov. 8, 2024, the company reported a cash position of $13.6 million, providing sufficient runway to support all Phase 3 preparatory activities and to initiate the pivotal Phase 3 Alzheimer’s study in Q1 2025.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap.
Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and…
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN